Improving medical communication in preventive medicine and health screening.
Health screening plays an important role in preventive medicine in Japan. Many healthcare institutions provide comprehensive health screening programs that include laboratory tests, imaging examinations, and lifestyle assessment.
In recent years, the number of international patients receiving health screening in Japan has increased. As a result, the need for clear and natural medical English communication has become increasingly important.
However, many medical reports are still translated directly from Japanese, which can lead to unnatural expressions or misunderstandings. Accurate and well-structured medical English is essential for effective communication with international patients and overseas physicians.
Hama Health focuses on improving medical communication in health screening through the development of standardized English medical comments and reporting templates.
Our work supports physicians and healthcare institutions by providing guidance on medical English writing, clinical documentation, and communication for international patients.
By improving the clarity and quality of medical reports, healthcare providers can deliver more effective preventive care and strengthen international medical collaboration.
Hama Health develops practical medical English resources for health screening and international medical communication in Japan.
Japan has a well-established system of health screening that plays an important role in preventive medicine. Comprehensive screening programs often include laboratory testing, imaging studies, and lifestyle assessments designed to detect early signs of disease.
With the increasing number of international residents and visitors in Japan, healthcare providers are encountering more patients who require medical explanations in English.
Effective communication is essential not only for explaining test results but also for providing reassurance and appropriate follow-up recommendations.
However, health screening reports are frequently translated directly from Japanese, which can result in expressions that are difficult for international patients to understand.
Clear and structured medical English helps physicians explain findings more effectively and ensures that patients receive accurate information about their health status.
Standardized medical English expressions and reporting templates can improve consistency, reduce misunderstandings, and support better communication between physicians and patients.
Hama Health supports healthcare institutions by providing guidance on medical English reporting, health screening communication, and international patient support in Japan.
This initiative is part of the Hama Health Medical English Project for improving clinical communication in preventive medicine.
Developing practical medical English resources for health screening in Japan.
Clear and accurate medical communication is essential in modern healthcare, especially when caring for international patients.
In Japan, health screening plays a central role in preventive medicine. However, medical explanations and reports are often translated directly from Japanese, which may lead to expressions that are difficult for international patients to understand.
The Hama Health Medical English Project aims to improve medical communication in health screening by developing practical medical English resources.
The project focuses on creating standardized English templates for health screening reports, clinical explanations, and follow-up recommendations.
These resources are designed to support physicians, healthcare institutions, and medical staff in communicating clearly with international patients.
Areas of development include:
Medical English comment templates for health screening
Standardized explanations for common clinical findings
English reporting templates for preventive medicine
Communication support for international patients
Through this initiative, Hama Health seeks to contribute to better medical communication and international collaboration in healthcare.
人間ドック不要論への反論 — エビデンスにもとづく再評価
Re-examining the case for comprehensive health screening in Japan in light of modern evidence.
Introduction
Ningen Dock（人間ドック）— Japan's tradition of comprehensive health screening — has played a central role in preventive medicine for over six decades. It combines laboratory testing, imaging studies, physical examination, and lifestyle assessment in a single, structured visit, with the goal of detecting disease at a stage when intervention is most effective.
In recent years, however, a growing voice — including online medical commentators with substantial audiences — has questioned whether comprehensive health screening is worthwhile at all. The argument is almost invariably traced to a single source: a Cochrane systematic review by Krogsbøll and colleagues, first published in 2012 and updated in 2019, which concluded that "general health checks" did not significantly reduce overall mortality or cardiovascular mortality. From this single conclusion, "the human dock is unnecessary"（「人間ドック不要論」）has been repeated in lay media, in social media, and in popular YouTube content reaching hundreds of thousands of viewers.
What is rarely mentioned — by either critics or, often, by the medical professionals who echo their claims — is what the Cochrane review actually evaluated.
This article offers an evidence-based response to that skepticism. It examines the actual content of the trials included in the Cochrane review, demonstrates the substantial gap between those interventions and modern Japanese Ningen Dock, and explains why a structured, evolving model of health screening — rather than its abandonment — best serves preventive medicine in Japan.
What the Cochrane Review Actually Studied
The 2019 Cochrane update included 17 randomized trials with approximately 251,000 participants. Repeated as a headline statistic, this sounds definitive. But a direct reading of the Cochrane review's Characteristics of Included Studies table reveals something quite different.
The included trials were conducted between 1963 and 1999. Six of the seventeen trials began in the 1960s. Not a single included trial began after the year 2000.
The interventions evaluated in these trials — taken directly from the Cochrane review's own documentation — consisted primarily of:
Göteborg 1963 (Sweden): Blood pressure, ECG, urinalysis, basic blood chemistry, chest X-ray, general examination
Kaiser Permanente 1965 (USA): Blood pressure, ECG, chest X-ray, mammography, vision/hearing, basic blood panel
South-East London 1967 (UK): Brief examination, height/weight, vision/hearing, chest X-ray, ECG, basic chemistry, fecal occult blood
Malmö 1969 (Sweden): Blood pressure, cholesterol, ECG, chest X-ray, lung function
WHO 1971 (multinational): Blood pressure, total cholesterol, weight, smoking questionnaire
Salt Lake City 1972 (USA): Multiphasic check with chest X-ray, ECG, basic blood tests, mammography, cervical cytology
OXCHECK 1989 (UK): Blood pressure, total cholesterol, height/weight, lifestyle questionnaire (nurse-led)
Family Heart 1990 (UK): BMI, blood pressure, total cholesterol, random glucose, Dundee risk score
Ebeltoft 1992 (Denmark): ECG, total cholesterol, blood pressure, lung function, basic chemistry, urine dipstick
Inter99 1999 (Denmark): Blood pressure, fasting lipids, oral glucose tolerance test, lung function, PRECARD risk assessment
This is the totality — or close to it — of what the Cochrane review actually measured.
Now consider the modern Japanese Ningen Dock examination. A standard comprehensive program typically includes diagnostic modalities that fall into three clear categories when compared to the Cochrane review's evidence base:
✅ Modalities included in some Cochrane trials:
Blood pressure measurement (in 15 of 17 included trials)
Total cholesterol (in most trials, though using 1960s–1990s methodology)
Basic blood chemistry (in some trials)
Chest X-ray (in 5 older trials, all before 1973)
⚠️ Modalities included in only 1–3 old trials:
Abdominal ultrasound — only one trial (DanMONICA 1982)
Mammography — three trials, all using film-era equipment
Cervical cytology — three trials, using pre-modern protocols
Fecal occult blood — one trial (South-East London 1967), using guaiac-based methods rather than modern FIT
❌ Modalities NOT included in ANY Cochrane trial:
HbA1c-based diabetes diagnosis
Upper gastrointestinal endoscopy (gastric cancer screening)
Lower GI endoscopy or modern fecal immunochemical testing
Low-dose CT for lung cancer screening
MRI of any organ
FIB-4 for liver fibrosis stratification
Bone mineral density measurement (DXA)
Helicobacter pylori serology
Hepatitis B / C virus screening
Multi-component cardiovascular risk scores (JSH2025, Hisayama)
Modern lipid stratification (LDL subclasses, non-HDL cholesterol)
Carotid intima-media thickness measurement
Echocardiography
The diagnostic modalities that define a modern Japanese Ningen Dock — gastrointestinal endoscopy, abdominal ultrasound, low-dose CT, FIB-4, modern cancer screening, contemporary risk stratification — were almost entirely absent from the trials the Cochrane review evaluated.
To cite this review as evidence that "Ningen Dock is unnecessary" is, quite simply, a category error. It is the equivalent of citing a 1965 study on simple aspirin trials as evidence that modern interventional cardiology is ineffective. The interventions evaluated bear only superficial resemblance to what is actually delivered in a modern comprehensive Japanese health screening program.
This is not a subtle methodological point. The Cochrane review's authors themselves explicitly acknowledged that "most trials were old" and that thresholds for treatment, risk assessment methods, and available preventive interventions have changed substantially since. Yet this caveat is rarely mentioned by those who cite the review's headline conclusion.
A Note on Responsible Citation of Evidence
It is one thing for a lay reader to repeat a misleading summary of a complex systematic review. It is another for medical professionals — including those with substantial public platforms — to do the same. The responsibility of evidence-based medicine includes reading beyond the abstract: asking what trials were included, when they were conducted, what they actually measured, and whether the conclusions can reasonably be extended to interventions that bear little resemblance to what was studied.
The Cochrane Collaboration itself has formally clarified this. The Cochrane Handbook for Systematic Reviews of Interventions explicitly states that a Cochrane review is one source of evidence rather than a final verdict, and that its conclusions must be interpreted alongside guideline recommendations, real-world data, and the clinical context in which screening is delivered.
A 2022 systematic review by Schmidt and colleagues further documented that the majority of medical interventions evaluated in recent Cochrane reviews are not supported by high-quality evidence — meaning that "Cochrane found no benefit" frequently reflects evidence gaps rather than proven absence of benefit. The distinction is critical: absence of evidence is not evidence of absence.
Modern guideline bodies — including the National Institute for Health and Care Excellence (NICE) in the United Kingdom, the US Preventive Services Task Force, the World Health Organization, and the Japanese Minds guideline library — continue to incorporate Cochrane reviews as one important source among many. None treats them as a stand-alone basis for discontinuing established screening programs.
The Japanese Evidence: A Different Picture
When the question is reframed from "do brief primary-care risk factor checks from the 1960s–1990s reduce all-cause mortality?" to "does comprehensive screening, as practiced in modern Japan, improve outcomes for the population it serves?", the evidence becomes considerably more favorable — and the Cochrane review, on this reframed question, simply does not apply.
Japanese population data show that organized cancer screening programs have contributed to declining mortality from gastric, colorectal, and cervical cancers over recent decades. Cardiovascular risk identification through hypertension, lipid, and glucose screening — followed by lifestyle counseling and, where appropriate, pharmacological treatment — is one of the most cost-effective interventions in medicine, with consistent international evidence supporting blood pressure control, statin therapy in selected populations, and glycemic management.
Modern Ningen Dock（人間ドック）has evolved continuously. Contemporary programs incorporate the Hisayama cardiovascular risk score, the JSH2025 hypertension framework, the JDS 2024 diabetes diagnostic criteria, the JAS 2022 atherosclerosis guideline, FIB-4 for liver fibrosis stratification, low-dose CT for lung cancer screening in high-risk smokers (per NLST and NELSON evidence showing 20–24% mortality reduction), and upper GI endoscopy for early gastric cancer detection. None of these modalities was evaluated in any of the trials included in the Cochrane review.
Addressing the Common Criticisms
Overdiagnosis. This is a real phenomenon and deserves serious attention. The well-known example of thyroid cancer screening in South Korea — where intensive ultrasound screening led to a large rise in incidence without a corresponding fall in mortality — is frequently cited as a warning. The response, however, is not to abandon screening but to design it intelligently. Active surveillance protocols, evidence-based thresholds for intervention, and careful patient communication can mitigate overdiagnosis without sacrificing early detection. The net benefit — not the absence of any harm — should be the criterion for evaluating screening.
Lead-time and length bias. These statistical phenomena can make screening appear to extend life when it merely shifts the moment of diagnosis. They are real considerations in trial design but do not affect the underlying biology: detecting and treating a cancer at stage I rather than stage IV materially changes the patient's prognosis. Randomized trials with mortality endpoints — including the NLST and NELSON trials for lung cancer screening — control for these biases. These are precisely the modern trials, evaluating precisely the modern modalities, that were not included in the Cochrane review on general health checks.
Cost-effectiveness. Critics sometimes argue that screening costs outweigh benefits. In the Japanese context, where Ningen Dock（人間ドック）is largely funded through employer health insurance and personal payment, the cost structure differs fundamentally from the public-health-funded mass screening programs evaluated in many international studies. Moreover, the early identification of hypertension, diabetes, and dyslipidemia — conditions that, untreated, lead to expensive late-stage cardiovascular and renal complications — generates downstream savings that are rarely captured in screening-only cost analyses.
The Path Forward: Evolve, Not Abandon
The honest answer to "is general health screening effective?" is that it depends on what is screened, how, in whom, and with what follow-up. A poorly designed screening program can produce more harm than benefit. A well-designed one — with evidence-based thresholds, integrated cardiovascular risk assessment, structured referral pathways, and clear patient communication — is among the most impactful tools in preventive medicine.
The future of Ningen Dock（人間ドック）lies not in retreat but in continuous refinement: incorporating updated guidelines as they emerge, removing tests that no longer meet evidence standards, integrating new modalities such as low-dose CT for high-risk smokers and FIB-4 for liver disease stratification, and — critically — communicating findings clearly so that patients can act on them.
This last point is where medical communication intersects with clinical evidence. A screening finding has value only when the patient understands what it means and what to do next. For international patients in Japan, this requires not only accurate clinical assessment but also clear, well-structured medical English — an area where standardized reporting templates and consistent terminology make a measurable difference.
Conclusion
Ningen Dock（人間ドック）is not above critique. Programs must be regularly re-examined against current evidence, tests that no longer meet contemporary standards should be retired, and individual screening modalities should each be judged on their own evidence base. The legitimate questions raised by overdiagnosis research, by individual-test effectiveness studies, and by health-economics analyses all deserve serious engagement.
But the broader argument that comprehensive health screening is fundamentally unnecessary rests on a citation chain that, when traced to its source, dissolves. The Cochrane review on general health checks evaluated trials beginning between 1963 and 1999, primarily measuring blood pressure, cholesterol, and basic risk factors in primary-care settings. It did not evaluate gastrointestinal endoscopy. It did not evaluate abdominal ultrasound. It did not evaluate low-dose CT. It did not evaluate HbA1c-based diabetes diagnosis. It did not evaluate FIB-4. It did not evaluate any of the modalities that define a modern Japanese Ningen Dock.
To repeat the review's headline conclusion as evidence against modern comprehensive screening — without acknowledging what was actually studied — is not evidence-based medicine. It is the appearance of evidence-based medicine, used to support a conclusion the evidence does not establish.
Comprehensive health screening, properly designed and clearly communicated, remains one of the most valuable contributions modern medicine can make to long-term population health. At Hama Health, we believe this value is worth defending — and worth communicating, in clear medical English, to the international patients and physicians who increasingly form part of the Japanese healthcare landscape.
This article is part of the Hama Health Medical English Project, which develops practical resources for medical communication in preventive medicine and health screening in Japan.
A comprehensive Japanese-language treatise on this topic — 「人間ドック不要論への反論 — エビデンスにもとづく再評価」 (46 pages, 49 references) — is available for colleagues who wish to read the full evidence review, including a detailed examination of each of the 17 trials included in the Cochrane review. Please contact Hama Health for access.
In the examination rooms of Japanese health screening centers, a quiet transformation has been underway for years. The patients sitting across from physicians are no longer exclusively Japanese speakers. International executives stationed in Tokyo, foreign workers employed under Japan's expanding labor programs, visiting family members of residents, and returning Japanese nationals who completed their education abroad increasingly find themselves in the Ningen Dock waiting room — and, eventually, in the consultation itself.
For the physician, this shift presents a challenge that is rarely discussed in medical education: how to explain a borderline HbA1c result, a mildly elevated ALT, or a recommendation for follow-up colonoscopy in English that is not only grammatically correct but clinically precise and humanly appropriate.
This article explains why we decided to write a textbook to address that gap — and what twenty years of practice in Japanese preventive medicine taught us about the intersection of language, evidence, and patient care.
Japan's Ningen Dock is among the most comprehensive health screening systems in the world. A single visit encompasses laboratory testing, imaging studies, physical examination, and structured lifestyle assessment, followed by a physician consultation in which findings are explained and recommendations are made. The system serves millions of people annually and has contributed to Japan's position among the nations with the highest healthy life expectancy.
Yet for all its structural sophistication, one element has remained conspicuously underdeveloped: the language of the consultation itself when the patient does not speak Japanese.
Medical English education in Japan has traditionally focused on academic presentation — reading journal articles, writing abstracts, delivering conference talks. These are important skills, but they address a different problem. The physician sitting across from a nervous international patient who has just been told that his blood pressure is 148 over 94 does not need to discuss the latest randomized controlled trial. He needs to say, clearly and kindly: "Your blood pressure is elevated. This does not mean you need medication today, but it does mean we need to pay attention. Let me explain what we can do."
No textbook taught this. No training program addressed it. The physicians who encountered these situations — and they were becoming more frequent every year — were left to improvise.
Over two decades of practice in health screening, we accumulated a body of practical knowledge that existed nowhere in written form. It was the knowledge of the examination room: which phrases reassured, which ones alarmed, which explanations led to follow-through and which were forgotten by the time the patient reached the elevator.
We learned that the most dangerous phrase in health screening is not an abnormal finding — it is "watchful waiting" delivered without specificity. Patients who are told "let's just observe this" frequently interpret it as "nothing needs to be done." The physician means something quite different: "We will monitor this actively, at defined intervals, with specific criteria for escalation." The gap between those two interpretations is where preventive medicine fails.
We learned that a three-second clinical judgment — the near-instantaneous assessment of whether a finding requires observation, referral, or intervention — is invisible to the patient unless it is accompanied by a three-hundred-second explanation. The speed of the judgment is a product of experience. The quality of the explanation is a product of preparation. Both are professional skills, but only one can be taught from a textbook.
And we learned that the same clinical scenario — a borderline blood pressure reading, a mildly abnormal liver enzyme, a finding that requires follow-up imaging — can produce dramatically different outcomes depending on the words chosen to describe it. Language is not decoration in preventive medicine. It is part of the intervention.
The decision to write Medical English for Health Screening was not made lightly. We were aware that a textbook is, by nature, a static object — and that clinical communication is dynamic, contextual, and deeply human. No template can replace judgment. No script can substitute for empathy.
But we also recognized that the absence of any structured resource was itself a barrier to quality. Physicians who encountered English-speaking patients for the first time had no framework. Those who had developed their own approaches over years of trial and error had no way to share them. The knowledge was atomized — present in individual practitioners but absent from the collective infrastructure of Japanese preventive medicine.
The textbook was designed to fill that gap. It is organized around twenty Clinical Decision Sheets (CS-01 through CS-20), each addressing a common finding or clinical scenario encountered in health screening, and twenty Practical Clinical Templates (PT-01 through PT-20), each providing structured language for patient communication. The total volume runs to 654 pages — not because we sought comprehensiveness for its own sake, but because the complexity of real clinical encounters demanded it.
Each Clinical Decision Sheet follows the same structure: clinical significance, key points, clinical situation factors, findings mapping, clinical recommendations, coordination with related findings, a short practical version for use during the consultation itself, and a conclusion. The structure mirrors the cognitive process of an experienced screening physician — from recognition through evaluation to communication — and is designed to be used not as a reference to be read cover to cover, but as a working tool to be consulted at the point of care.
The Practical Clinical Templates take a different approach. Rather than providing scripts to be recited, they offer frameworks for structuring patient conversations: how to open, how to present the finding, how to contextualize the risk, how to recommend next steps, and how to close with clarity about follow-up. The templates are deliberately written in plain, direct English — the language of the examination room, not the lecture hall.
The decision to write the textbook in English rather than Japanese was driven by the nature of the problem it addresses. The physicians who need this resource are Japanese. The patients they serve are not. The gap exists precisely at the point where a Japanese-trained physician must communicate clinical findings in a language that is not their own — and where the patient's understanding, compliance, and peace of mind depend on the quality of that communication.
Japan's international patient population is growing. The government's health tourism initiatives, the expansion of work-based residency programs, and the increasing globalization of the Japanese workforce all point in the same direction: the physicians who staff the nation's health screening centers will encounter more international patients, not fewer, in the years ahead.
At the same time, the standards of clinical communication are rising. Patients — Japanese and international alike — expect explanations that are clear, evidence-based, and respectful of their autonomy. The era of paternalistic medicine, in which the physician's recommendation was accepted without question, has given way to an era of shared decision-making, in which the quality of the explanation is itself a measure of the quality of care.
A textbook that standardizes the language of health screening communication is not merely a convenience. It is a quality improvement tool — one that addresses the final, and often neglected, step in the preventive medicine pipeline: the moment when a finding is translated into understanding, and understanding into action.
We want to be clear about what this textbook does not attempt to do.
It is not a substitute for clinical judgment. The decision sheets provide frameworks, not mandates. Every patient encounter is unique, and the templates must be adapted to the individual sitting in front of the physician.
It is not a comprehensive medical English course. It does not teach grammar, pronunciation, or general medical vocabulary. It assumes that the reader is a trained physician with functional English who needs structured, clinically precise language for a specific context: the health screening consultation.
And it is not a static document. Clinical guidelines evolve, and the language of medicine evolves with them. We intend to update the content as guidelines change — as new evidence emerges, as screening modalities are added or retired, and as the needs of the international patient population in Japan continue to develop.
Beyond its immediate practical function, this textbook is part of a broader effort: to make Japanese preventive medicine accessible to the world.
Japan's Ningen Dock system is, in our assessment, one of the most sophisticated preventive health infrastructures in existence. Its integration of comprehensive testing, structured follow-up, and physician-led counseling represents a model that other nations could learn from. Yet it remains largely invisible to the international medical community — not because it lacks merit, but because it has not been adequately described in the language of international medicine.
By standardizing the English used in health screening communication, we hope to contribute to a larger goal: ensuring that the value of Japanese preventive medicine is recognized not only by those who experience it directly, but by the physicians, researchers, and policymakers around the world who shape the future of preventive care.
We wrote this textbook because the need was real, the gap was unfilled, and twenty years of practice had given us something to say. It is, we believe, the first resource of its kind: a comprehensive, clinically grounded guide to medical English in the context of Japanese health screening.
It is now available in both Kindle and paperback editions through Amazon Japan. We offer it to our colleagues — in Japan and beyond — in the hope that it will be useful at the point where it matters most: in the examination room, at the moment of explanation, in the space between a finding and a patient's understanding of what comes next.
That space is where preventive medicine either succeeds or fails. We wrote this book to help it succeed.
———
This article is part of the Hama Health Medical English Project, which develops practical resources for medical communication in preventive medicine and health screening in Japan.
Medical English for Health Screening: The Hama Health Clinical Sheet Manual is available on Amazon Japan in Kindle (¥1,499) and Paperback (¥5,500) editions.